Comparative Pharmacology
Head-to-head clinical analysis: MICRO K 10 versus MICRO K LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICRO K 10 versus MICRO K LS.
MICRO-K 10 vs MICRO-K LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.
Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.
10 mEq (2 capsules) orally once daily, or 20 mEq (2 capsules) twice daily, or as directed by physician. Maximum 100 mEq/day.
10-20 mEq (as potassium chloride) orally twice daily; maximum 100 mEq/day.
None Documented
None Documented
Not applicable; potassium is not cleared by first-order kinetics. Whole-body potassium turnover half-life is approximately 30 days, but this is not clinically relevant for supplementation.
Not applicable (K+ is an electrolyte, not eliminated by first-order kinetics). Clinical context: Serum K+ decline follows redistribution and excretion with a half-life of ~2-4 hours after IV bolus.
Primarily renal: 90% of absorbed potassium is excreted in urine as potassium ions; 10% eliminated in feces via biliary and intestinal secretion.
Renal: ~90% as KCl (proportional to intake). Biliary/fecal: <10%.
Category C
Category C
Electrolyte Supplement (Potassium)
Electrolyte Supplement (Potassium)